Dr. Naiyer A. Rizvi is a medical oncologist with specific expertise in thoracic oncology and immunotherapy drug development. Dr. Rizvi is the Price Chair of Clinical Translational Medicine at Columbia University Medical Center (CUMC). He is also the Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy at CUMC. He obtained his M.D. at University of Manitoba in Winnipeg, Canada and went on to complete a fellowship in medical oncology at Beth Israel Hospital/Harvard Medical School. He was an attending physician in thoracic oncology and early drug development from 2002-2014 at Memorial Sloan Kettering Cancer Center (MSKCC) where Dr. Rizvi’s translational research was focused on immune-checkpoint blockade drug development. His research studies were integral to the approval of immune-checkpoint blockade in lung cancer including approval of nivolumab in squamous lung cancer (Lancet Oncology 2015) and pembrolizumab in non-small cell lung cancer (NEJM, 2015). His first-author publication in Science (2015) presented data from a landmark trial – the first study to demonstrate a statistically significant correlation between mutations and neo-antigens with durable benefit to immune-checkpoint blockade. His ongoing work is to understand mechanisms of sensitivity and resistance to immunotherapy.